DiamiR and AlzLabs Team Up on Blood-Based Alzheimer's Biomarkers
Aptorum Group-backed DiamiR Biosciences and AlzLabs Precision Diagnostics are joining forces to develop protein and microRNA blood tests for Alzheimer's detection.
If you've ever wondered whether a simple blood draw could one day flag Alzheimer's disease before symptoms spiral, two diagnostics companies are working on exactly that. Aptorum Group (NASDAQ: APM), a clinical-stage biopharmaceutical firm, announced a new collaboration between its portfolio company DiamiR Biosciences and AlzLabs Precision Diagnostics aimed squarely at blood-based biomarkers for Alzheimer's disease.
The partnership will focus on generating data around two types of biomarkers: proteins and microRNAs — tiny molecules that help regulate gene activity. Think of them as biological breadcrumbs your blood leaves behind that researchers can potentially read like a diagnostic report card. The goal is to identify reliable signals in the bloodstream that correlate with Alzheimer's, which could eventually make early detection far less invasive and more accessible than current methods like PET scans or spinal fluid tests.
Read more Outback Steakhouse Rival Shuts 24 Locations After 52 Years →
DiamiR brings its expertise in innovative blood-based diagnostic tests for brain health to the table, while AlzLabs Precision Diagnostics contributes its focus on Alzheimer's-specific research. Together, the collaboration is designed to pool complementary strengths and accelerate the data generation needed to validate these biomarker approaches — a critical step before any test can move toward clinical or commercial use.
Alzheimer's disease remains one of the most pressing unmet medical needs in neurology, affecting millions of Americans and placing an enormous burden on caregivers and the healthcare system. Blood-based diagnostics represent a promising frontier because they could enable earlier intervention, potentially at a point when treatments are more effective. While the collaboration is still in early stages, the combination of protein and microRNA analysis could offer a more comprehensive biomarker picture than single-marker approaches.
Continue reading at GlobalNewswire.
